Allon Therapeutics, Inc.

此轮融资将用于公司进一步发展，帮助Ozette Technologies能够在多组学平台上扩展其能力，整合单细胞蛋白质组学和转录组学。 Ventures领投的2600万美元A轮融资，其他投资者包括Cercano Management（之前是Vulcan Capital）、M12、微软风险基金、Alexandria Venture Investments、OCV Partners和杜克大学。 2021年2月16日，Ozette Technologies完成了600万美元种子轮融资，由Madrona Venture领投，AI2和Vulcan Capital跟投。 此轮融资将用于公司进一步发展，帮助Ozette Technologies能够在多组学平台上扩展其能力，整合单细胞蛋白质组学和转录组学。与此同时，Ozette Technologies正在建议一个新的免疫学实验室，该实验室将帮助Ozette Technologies的合作伙伴利用其技术，进一步实现垂直整合的自动化免疫分析。 Ozette Technologies 2020年于美国纽约成立,由Fred Hutchinson癌症中心分拆而生，并在艾伦人工智能研究所孵化成熟，Ozette的跨学科团队由一群资深的科学家、工程师和设计师组成，他们在基因泰克、谷歌、微软、亚马逊、Airbnb等拥有广泛的经验。最近招聘的知名人士包括Ozette的工程副总裁Amarjit Kaur，此前他曾在SayKara/Nuance（被微软收购）任职。 官网信息显示，Ozette Technologies 正在使用新的算法和机器学习将生物学数字化，以更为细致了解人类免疫系统的全貌。通过数字化免疫数据，Ozette Technologies 加快了创新疗法和诊断技术的开发。Ozette Technologies 设想未来了解免疫系统的状态将成为日常生活的一部分。 官网信息显示，Ozette Technologies 的智能计算分析技术将释放单细胞数据的全部潜力，其AI驱动的数据分析能力来源于在Fred Hutchinson癌症中心开创并在艾伦人工智能研究所 (AI2) 孵化的研究。Ozette Technologies 的早期合作伙伴包括开发肿瘤学、自身免疫性疾病和传染病疗法的小型到大型生物制药公司。Ozette Technologies 将开启计算免疫学的新前沿，加速生物标志物和药物发现的下一波浪潮。 Ozette Technologies 首席执行官兼联合创始人Ali Ansary博士表示：“Ozette的技术使合作伙伴摆脱了劳动密集型的手动分析方法，并通过整合、可搜索的免疫数据推动我们走向未来，从而改变治疗发现和开发。” “我们设计了一个基于机器学习的计算平台，可以在几天内完成数月的分析工作，我们正在努力将其缩短到几分钟。Ozette代表了在细胞水平上完全解析免疫状态画像最前沿的创新，将提供给科学家可以信赖的透明、可验证和可重复的高分辨率分析结论。”

VANCOUVER, BRITISH COLUMBIA--(Marketwire - November 10, 2010) - Allon Therapeutics Inc. (TSX: NPC) announced today that Professor Illana Gozes, Allon's founding scientist and the discoverer of Allon's clinical-stage neuroprotective drug candidate davunetide, has been awarded the Olson Prize for her research insights into the behavioral effects of peptides by the journal PEPTIDES. Awarded annually for the most meritorious original research article on the behavioral effects of peptides published during the previous year, the Olson Prize honors the outstanding contributions of Drs. Gayle A. and Richard D. Olson to the field of peptide research. Prof. Gozes' article, entitled "NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse-A microtubule-deficient model of schizophrenia", was published in PEPTIDES in April 2010, and involved studies in mice that are bred to be deficient in a protein called stable tubule-only polypeptide (STOP) protein. Associated with proper function of microtubular network, the STOP protein is important for the survival of the nerve cell. The deficient mice are a reliable model for schizophrenia and, in Prof. Gozes' study, the mice showed schizophrenia-like symptoms (hyperactivity) that were ameliorated by chronic treatment with the antipsychotic drug, clozapine. Prof. Gozes' study showed that daily intranasal treatment with NAP (davunetide) significantly decreased hyperactivity and also protected the visual memory of the STOP-deficient mice. This result is consistent with previous research by Prof. Gozes in mouse models where brain pathology is characterized by the hyperphosphorylation of the microtubule-associated protein tau, often referred to as tauopathies. Prof. Gozes' research has shown that davunetide increases the ratio of non-phosphorylated tau to phosphorylated tau, resulting in the maintenance of the essential microtubular network. These results, and Allon's clinical development program, suggest that davunetide is the most advanced tau-targeting drug candidate in clinical development. Allon expects to have started the progressive supranuclear palsy (PSP) study before the end of this quarter. PSP is a type of frontotemporal dementia (FTD) where there are extensive tauopathies. FTD is a group of rapidly progressive and fatal degenerative brain diseases, often misdiagnosed as Parkinson's or Alzheimer's disease. The Company has previously demonstrated human efficacy in amnestic mild cognitive impairment, a precursor to Alzheimer's disease, and cognitive impairment associated with schizophrenia. Prof. Gozes, Ph.D, is a Professor of Clinical Biochemistry at the Sackler Faculty of Medicine of Tel Aviv University. She is the Lily and Avraham Gildor Chair for the Investigation of Growth Factors and the Director of the Adams Super Center for Brain Studies and the Edersheim Levie-Gitter Institute for Functional Brain Imaging. Prof Gozes is also Head of the Dr. Diana and Zelman Elton (Elbaum) Laboratory for Molecular Neuroendocrinology. Prof. Gozes serves or has served as a member (or chair) of several faculty/university/national and international committees and is currently the Editor-in Chief of the Journal of Molecular Neuroscience and the President of the Israel Society for Neuroscience. Collaborative research led by Prof. Gozes has been supported by Allon, Tel Aviv University, the U.S. National Institutes of Health and the Canadian Friends of Tel Aviv University. Co-authors of the award-winning article are students Avia Merenlender-Wagner, Regina Pikman, and research staff Dr. Eliezer Giladi, at Prof. Gozes laboratory at Tel Aviv University, and Dr. Annie Andrieux, of the Institut des Neurosciences de Grenoble, Universite Joseph Fourier and Institut de Recherches en Technologies et Sciences pour le Vivant Direction des Sciences du Vivant, Grenoble, France. About Allon's neuroprotective platforms Allon's two neuroprotective technology platforms are based on two naturally occurring proteins produced by the brain in response to a range of insults. The platforms are activity-dependent neuroprotective protein (ADNP) and activity-dependent neurotrophic factor (ADNF). Because the two platforms are based on different proteins, the drugs from each are different molecules with different therapeutic mechanisms and distinct commercial opportunities. Clinical-stage drugs based on davunetide are derived from ADNP, while preclinical stage drug AL-309 is derived from ADNF. Davunetide is focused on Alzheimer's disease, cognitive impairment associated with schizophrenia, and progressive supranuclear palsy (PSP). AL-309 is being developed for the treatment of peripheral neuropathies and is administered orally or subcutaneously. About Allon Allon Therapeutics Inc. is a clinical-stage biotechnology company developing treatments for major neurodegenerative conditions. Allon's drug davunetide has demonstrated human efficacy in amnestic mild cognitive impairment, a precursor to Alzheimer's disease, and cognitive impairment associated with schizophrenia. Allon has Phase 2 human efficacy programs pursuing large underserved markets, such as Alzheimer's disease and cognitive impairment associated with schizophrenia, and in orphan markets, such as frontotemporal dementias. The Company is listed on the Toronto Stock Exchange under the trading symbol "NPC" (Neuro Protection Company™) and based in Vancouver. For additional information please visit the Company's website: . Forward Looking Statements Statements contained herein, other than those which are strictly statements of historical fact may include forward-looking information. Such statements will typically contain words such as "believes", "may", "plans", "will", "estimate", "continue", "anticipates", "intends", "expects", and similar expressions. While forward-looking statements represent management's outlook based on assumptions that management believes are reasonable, forward-looking statements by their nature are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by them. Such factors include, among others, the inherent uncertainty involved in scientific research and drug development, Allon's early stage of development, lack of product revenues, its additional capital requirements, the risks associated with successful completion of clinical trials and the long lead-times and high costs associated with obtaining regulatory approval to market any product which Allon may eventually develop. Other risk factors include the limited protections afforded by intellectual property rights, rapid technology and product obsolescence in a highly competitive environment and Allon's dependence on collaborative partners and contract research organizations. These factors can be reviewed in Allon's public filings at and should be considered carefully. Readers are cautioned not to place undue reliance on such forward-looking statements. Contacts: Allon Therapeutics Inc. - Investor Contact Aaron Keay Director, Investor Relations (604) 742-2540 or Cell: (604) 323-6911 akeay@allontherapeutics.com GCI Health - Media Contact Edie DeVine (415) 365-8543 edie.devine@gcihealth.com